Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

(2014) P. G. Richardson et al.   BLOOD

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

(2014) B. Escudier et al.   CLINICAL CANCER RESEARCH

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

(2013) E. Angevin et al.   CLINICAL CANCER RESEARCH

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

(2013) A J Jakubowiak et al.   LEUKEMIA

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

(2012) P. L. Bergsagel et al.   BLOOD

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

(2012) V Chell et al.   ONCOGENE

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies

(2012) A Kalff et al.   Blood Cancer Journal

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD